WO2025104695 - IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES THEREOF
National phase entry is expected:
Publication Number
WO/2025/104695
Publication Date
22.05.2025
International Application No.
PCT/IB2024/061417
International Filing Date
15.11.2024
Title **
[English]
IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES THEREOF
[French]
LIPIDES CATIONIQUES IONISABLES ET NANOPARTICULES LIPIDIQUES ASSOCIÉES
Applicants **
CORTI THERAPEUTICS PTE. LTD.
Inventors
HU, Qi-Ying
Priority Data
63/599,781
16.11.2023
US
63/693,874
12.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3721 | |
| EPO | Filing, Examination, Granting | 20512 | |
| Japan | Filing, Examination, Granting | 2646 | |
| South Korea | Filing, Examination, Granting | 2994 | |
| USA | Filing, Examination, Granting | 8240 |
Total:
38,113
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
) are as described herein. Also provided are lipid nanoparticles comprising ionizable lipids of Formula (I), or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and methods of using the ionizable lipids, e.g., to administer therapy to a subject in need thereof.[French]
) sont tels que décrits dans la description. L'invention concerne également des nanoparticules lipidiques comprenant des lipides ionisables de formule (I), ou un sel, un solvate ou un hydrate pharmaceutiquement acceptable de ceux-ci, et des procédés d'utilisation des lipides ionisables, par exemple, pour administrer une thérapie à un sujet en ayant besoin.